SITC 2022 - Posters will be presented in person at the Boston Convention & Exhibition Center on Thursday, November 10th, 2022
DATE: 11/9/2022
Precision Biologics, Inc. and National Cancer Institute Collaborators Deliver Poster Presentation at the ASCO Annual Meeting June 5, 2022
DATE: 6/5/2022
Clinical and Scientific Programs at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting
DATE: 11/13/21
Clinical and Scientific Programs at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting
DATE: 11/12/21
Precision Biologics and the National Cancer Institute deliver 2 Poster Presentations at the AACR virtual meeting June 22-24th, 2020
DATE: 06/22/2020
Indirect mechanisms of action of a novel IgG1 monoclonal antibody, NEO-201, to enhance immune killing of tumor.
DATE: 02/06/20
Phase 1 with Expansion Cohorts in a Study of NEO-201 in Adults with Chemo-Resistant Solid tumors
DATE: 01/25/20
An anti-carcinoma monoclonal antibody (mAb) NEO-201 can also target and eliminate human immunosuppressive regulatory T cells (Tregs)
DATE: 11/6/19
2016 ASCO Annual Meeting – A phase 2 study of NEO-102 (ensituximab), a novel chimeric monoclonal antibody, in adult patients (pts) with unresectable, metastatic colorectal cancer (mCRC).
DATE: 6/16/16